

Allan D Sniderman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4090705/publications.pdf>

Version: 2024-02-01

155
papers

9,766
citations

41344

49
h-index

38395

95
g-index

162
all docs

162
docs citations

162
times ranked

9373
citing authors

#	ARTICLE	IF	CITATIONS
1	Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk. <i>JAMA Cardiology</i> , 2022, 7, 257.	6.1	36
2	Key Questions About Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1023-1031.	2.8	15
3	An adverse lipoprotein phenotype hypertriglyceridaemic hyperapoprotein B and the long-term risk of type 2 diabetes: a prospective, longitudinal, observational cohort study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e339-e346.	4.6	5
4	Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles. <i>Journal of the Endocrine Society</i> , 2022, 6, .	0.2	2
5	Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm. <i>Journal of Clinical Lipidology</i> , 2021, 15, 104-115.e9.	1.5	6
6	A Comparison of Lipids and apoB in Asian Indians and Americans. <i>Global Heart</i> , 2021, 16, 7.	2.3	4
7	Update on apolipoprotein B. <i>Current Opinion in Lipidology</i> , 2021, 32, 226-230.	2.7	25
8	Clinical reasoning and prevention of cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2021, 15, 394-398.	1.5	1
9	Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives. <i>The Lancet Healthy Longevity</i> , 2021, 2, e317-e326.	4.6	41
10	Spectrum of Apolipoprotein AI and Apolipoprotein All Proteoforms and Their Associations With Indices of Cardiometabolic Health: The CARDIA Study. <i>Journal of the American Heart Association</i> , 2021, 10, e019890.	3.7	12
11	ApoB vs non-HDL-C vs LDL-C as Markers of Cardiovascular Disease. <i>Clinical Chemistry</i> , 2021, 67, 1440-1442.	3.2	14
12	Apolipoprotein B: the Rosetta Stone of lipidology. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 90-96.	2.3	10
13	How ApoB Measurements Could Improve Prevention of Cardiovascular Disease. <i>Contemporary Cardiology</i> , 2021, , 545-563.	0.1	0
14	The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. <i>Circulation</i> , 2020, 142, 827-837.	1.6	44
15	Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia). <i>Archives of Medical Science</i> , 2020, 16, 993-1003.	0.9	20
16	Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low-Density Lipoprotein Cholesterol The Framingham Heart Study. <i>Journal of the American Heart Association</i> , 2020, 9, e014711.	3.7	22
17	The clinical utility of apoB versus LDL-C/non-HDL-C. <i>Clinica Chimica Acta</i> , 2020, 508, 103-108.	1.1	27
18	Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?. <i>Current Cardiology Reports</i> , 2020, 22, 67.	2.9	42

#	ARTICLE	IF	CITATIONS
19	Prevention of cardiovascular disease: time for a course correction. <i>European Heart Journal</i> , 2020, 41, 3016-3017.	2.2	3
20	Trajectories of Non-HDL Cholesterol Across Midlife. <i>Journal of the American College of Cardiology</i> , 2019, 74, 70-79.	2.8	67
21	Apolipoprotein B Particles and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 1287.	6.1	299
22	Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. <i>JAMA Cardiology</i> , 2019, 4, 969.	6.1	30
23	Did the ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA cholesterol guidelines get apoB right?. <i>Journal of Clinical Lipidology</i> , 2019, 13, 360-366.	1.5	12
24	ApoB. <i>Circulation Research</i> , 2019, 124, 1425-1427.	4.5	25
25	Letter by Sniderman et al Regarding Article, "Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease". <i>Circulation</i> , 2019, 140, e822-e823.	1.6	0
26	ApoB in clinical care: Pro and Con. <i>Atherosclerosis</i> , 2019, 282, 169-175.	0.8	27
27	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. <i>Circulation</i> , 2019, 139, 1603-1611.	1.6	115
28	Type III Hyperlipoproteinemia: The Forgotten, Disregarded, Neglected, Overlooked, Ignored but Highly Atherogenic, and Highly Treatable Dyslipoproteinemia. <i>Clinical Chemistry</i> , 2019, 65, 225-227.	3.2	16
29	A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux Capacity. <i>Journal of Proteome Research</i> , 2018, 17, 2156-2164.	3.7	30
30	Response by Labos et al to Letter Regarding Article, "Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression". <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, e87-e88.	2.4	1
31	Serial versus single troponin measurements for the prediction of cardiovascular events and mortality in stable chronic haemodialysis patients. <i>Nephrology</i> , 2018, 23, 69-74.	1.6	9
32	Evaluation of the Pleiotropic Effects of Statins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 262-265.	2.4	32
33	The spectrum of type III hyperlipoproteinemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1383-1389.	1.5	40
34	A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention. <i>JAMA Cardiology</i> , 2018, 3, 1090.	6.1	27
35	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. <i>Journal of the American Heart Association</i> , 2018, 7, e009778.	3.7	67
36	Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated. <i>Journal of the American Heart Association</i> , 2018, 7, e010049.	3.7	15

#	ARTICLE	IF	CITATIONS
37	Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. <i>Journal of Lipid Research</i> , 2018, 59, 1266-1275.	4.2	62
38	A failure of standardization or a failure of the process of standardization. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1325-1326.	1.5	3
39	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. <i>Clinical Chemistry</i> , 2017, 63, 870-879.	3.2	74
40	Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte. <i>Clinical Science</i> , 2017, 131, 791-797.	4.3	5
41	Race and Socioeconomic Differences Associated With Changes in Statin Eligibility Under the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	7
42	The Benefit Model for Prevention of Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017, 2, 1175.	6.1	16
43	Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2017, 136, 1860-1862.	1.6	2
44	Genetic Studies Help Clarify the Complexities of Lipid Biology and Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 915.	7.4	5
45	Shunts, channels and lipoprotein endosomal traffic: a new model of cholesterol homeostasis in the hepatocyte. <i>Journal of Biomedical Research</i> , 2017, 31, 95-107.	1.6	8
46	World Heart Federation Cholesterol Roadmap. <i>Global Heart</i> , 2017, 12, 179.	2.3	30
47	Nutritional management of hyperapoB. <i>Nutrition Research Reviews</i> , 2016, 29, 202-233.	4.1	22
48	The Enigma of Glucose and Lipid Metabolism. <i>JAMA Cardiology</i> , 2016, 1, 145.	6.1	12
49	An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1248-1258.	1.5	29
50	Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosisâ€”Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2421-2423.	2.4	38
51	Age and Cardiovascular Risk Attributable to Apolipoprotein B, Lowâ€Density Lipoprotein Cholesterol or Nonâ€Highâ€Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	41
52	Risk of Premature Cardiovascular Disease vs the Number of Premature Cardiovascular Events. <i>JAMA Cardiology</i> , 2016, 1, 492.	6.1	52
53	Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification. <i>Journal of the American College of Cardiology</i> , 2016, 67, 193-201.	2.8	120
54	Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2016, 133, 1574-1581.	1.6	66

#	ARTICLE	IF	CITATIONS
55	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 103, 236-252.	7.1	60
56	Limitations in the conventional assessment of the incremental value of predictors of cardiovascular risk. <i>Current Opinion in Lipidology</i> , 2015, 26, 210-214.	2.7	12
57	Response to Letter Regarding Article, "Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease". <i>Circulation</i> , 2015, 132, e203.	1.6	2
58	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. <i>Journal of Clinical Lipidology</i> , 2015, 9, 511-518.e5.	1.5	5
59	Is the Guideline Process Replicable and, if Not, What Does This Mean?. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 3-9.	3.1	2
60	Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1321-1327.	1.8	112
61	Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. <i>Circulation</i> , 2015, 131, 451-458.	1.6	283
62	Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 468-477.	1.8	37
63	Screening Strategies and Primary Prevention Interventions in Relatives of People With Coronary Artery Disease: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2015, 31, 649-657.	1.7	9
64	Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. <i>Clinical Science</i> , 2015, 129, 63-79.	4.3	21
65	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2015, 132, 667-676.	1.6	41
66	The Role of Physicians in the Era of Predictive Analytics. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 25.	7.4	55
67	Approach and management of triglyceride based disorders. <i>Journal of Indian College of Cardiology</i> , 2015, 5, S66-S68.	0.1	0
68	Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1633-1639.	2.8	58
69	Risk Prediction for Individuals. Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1875.	7.4	2
70	JCL roundtable: Apolipoproteins as causative elements in vascular disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 733-740.	1.5	6
71	Proportion of US Adults Potentially Affected by the 2014 Hypertension Guideline. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1424.	7.4	95
72	Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. <i>Current Opinion in Lipidology</i> , 2014, 25, 461-467.	2.7	61

#	ARTICLE	IF	CITATIONS
73	Relations of Change in Plasma Levels of LDL-C, Non-HDL-C and apoB With Risk Reduction From Statin Therapy: A Meta-Analysis of Randomized Trials. <i>Journal of the American Heart Association</i> , 2014, 3, e000759.	3.7	104
74	Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials. <i>Journal of Clinical Lipidology</i> , 2014, 8, 441-447.	1.5	19
75	Calculation of LDL apoB. <i>Atherosclerosis</i> , 2014, 234, 373-376.	0.8	4
76	The Severe Hypercholesterolemia Phenotype. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1935-1947.	2.8	153
77	Application of New Cholesterol Guidelines to a Population-Based Sample. <i>New England Journal of Medicine</i> , 2014, 370, 1422-1431.	27.0	571
78	Taking a longer term view of cardiovascular risk: the causal exposure paradigm. <i>BMJ</i> , 2014, 348, g3047-g3047.	6.0	23
79	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 594-605.	1.5	11
80	Improving Recognition of Cardiovascular Risk in Children. <i>Journal of Pediatrics</i> , 2014, 164, 228-230.	1.8	6
81	Do statins lower testosterone and does it matter?. <i>BMC Medicine</i> , 2013, 11, 58.	5.5	6
82	Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008. <i>Cardiovascular Diabetology</i> , 2013, 12, 26.	6.8	18
83	Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables?. <i>Journal of Clinical Lipidology</i> , 2013, 7, 626-631.	1.5	14
84	Hepatic Cholesterol Homeostasis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2481-2490.	2.4	28
85	The Necessity for Clinical Reasoning in the Era of Evidence-Based Medicine. <i>Mayo Clinic Proceedings</i> , 2013, 88, 1108-1114.	3.0	77
86	ApoB versus non-HDL-cholesterol: Diagnosis and cardiovascular risk management. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2013, 50, 163-171.	6.1	21
87	Update on the detection and treatment of atherogenic low-density lipoproteins. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 140-147.	2.3	14
88	The causal exposure model of vascular disease. <i>Clinical Science</i> , 2012, 122, 369-373.	4.3	16
89	Low-density lipoprotein-lowering strategies. <i>Current Opinion in Cardiology</i> , 2012, 27, 405-411.	1.8	16
90	Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. <i>Atherosclerosis</i> , 2012, 225, 444-449.	0.8	105

#	ARTICLE	IF	CITATIONS
91	Comparison of Coronary Calcium Screening Versus Broad Statin Therapy for Patients at Intermediate Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2012, 110, 530-533.	1.6	7
92	Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein. <i>Journal of Clinical Lipidology</i> , 2012, 6, 427-433.	1.5	18
93	Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialistsâ€™ Collaboration meta-analysis for low-density lipoprotein lowering. <i>Journal of Clinical Lipidology</i> , 2012, 6, 303-309.	1.5	42
94	Pluralism of viewpoints as the antidote to intellectual conflict of interest in guidelines. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 705-707.	5.0	13
95	Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. <i>Journal of Clinical Lipidology</i> , 2011, 5, 264-272.	1.5	103
96	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	1.5	235
97	Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias. <i>European Journal of Clinical Investigation</i> , 2011, 41, 423-433.	3.4	11
98	Should preclinical vascular abnormalities be measured in asymptomatic adults to improve cardiovascular risk stratification?. <i>Current Opinion in Lipidology</i> , 2011, 22, 454-459.	2.7	3
99	A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 337-345.	2.2	491
100	Non-HDL C equals apolipoprotein B: except when it does not!. <i>Current Opinion in Lipidology</i> , 2010, 21, 518-524.	2.7	28
101	Regulation of plasma LDL: the apoB paradigm. <i>Clinical Science</i> , 2010, 118, 333-339.	4.3	49
102	Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. <i>Nature Reviews Endocrinology</i> , 2010, 6, 335-346.	9.6	99
103	Cardiovascular Death in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 335-340.	4.5	40
104	Apolipoprotein B, Diabetes and Medical Consensus. <i>Annals of Clinical Biochemistry</i> , 2010, 47, 2-3.	1.6	4
105	When is equal not equal?. <i>Journal of Clinical Lipidology</i> , 2010, 4, 83-88.	1.5	27
106	Why is nonâ€™high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?. <i>Journal of Clinical Lipidology</i> , 2010, 4, 152-155.	1.5	83
107	Why Guideline-Making Requires Reform. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 429.	7.4	184
108	ApoB versus non-HDL-C: What to do when they disagree. <i>Current Atherosclerosis Reports</i> , 2009, 11, 358-363.	4.8	36

#	ARTICLE	IF	CITATIONS
109	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Canadian Journal of Cardiology, 2009, 25, 567-579.	1.7	653
110	Targets for LDL-lowering therapy. Current Opinion in Lipidology, 2009, 20, 282-287.	2.7	21
111	The Editor's Roundtable: Expanded Versus Standard Lipid Panels in Assessing and Managing Cardiovascular Risk. American Journal of Cardiology, 2008, 101, 828-842.	1.6	9
112	Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. Journal of Clinical Lipidology, 2008, 2, 36-42.	1.5	101
113	Age as a modifiable risk factor for cardiovascular disease. Lancet, The, 2008, 371, 1547-1549.	13.7	125
114	Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	18.7	698
115	A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 608-618.	2.8	68
116	The case against ApoB and the ApoB:ApoA-I ratio: are they right?. Future Lipidology, 2008, 3, 257-264.	0.5	2
117	Diabetes, Abdominal Adiposity, and Atherogenic Dyslipoproteinemia in Women Compared With Men. Diabetes, 2008, 57, 3289-3296.	0.6	45
118	Non-HDL cholesterol and apoB in dyslipidaemia. Clinical Science, 2008, 114, 149-155.	4.3	23
119	Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. International Journal of Epidemiology, 2007, 36, 220-225.	1.9	263
120	Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Current Opinion in Lipidology, 2007, 18, 633-637.	2.7	64
121	Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. Journal of Clinical Lipidology, 2007, 1, 256-263.	1.5	64
122	Differential impact of plasma triglycerides on HDL-cholesterol and HDL-apo A-I in a large cohort. Clinical Biochemistry, 2007, 40, 25-29.	1.9	18
123	Relation of Age, the Apolipoprotein B/Apolipoprotein A-I Ratio, and the Risk of Fatal Myocardial Infarction and Implications for the Primary Prevention of Cardiovascular Disease. American Journal of Cardiology, 2007, 100, 217-221.	1.6	27
124	The strengths and limitations of the ApoB/ApoA-I ratio to predict the risk of vascular disease: a hegelian analysis. Current Atherosclerosis Reports, 2007, 9, 261-265.	4.8	19
125	Apolipoprotein A1 and B. Clinics in Laboratory Medicine, 2006, 26, 733-750.	1.4	44
126	The adipocyte life cycle hypothesis. Clinical Science, 2006, 110, 1-9.	4.3	85

#	ARTICLE	IF	CITATIONS
127	Does Low-Density Lipoprotein Size Add to Atherogenic Particle Number in Predicting the Risk of Fatal Myocardial Infarction?. American Journal of Cardiology, 2006, 97, 943-946.	1.6	61
128	Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, or Apolipoprotein B. American Journal of Cardiology, 2005, 96, 36-43.	1.6	54
129	Atherosclerosis Risk Factors. James J. Maciejko. Washington, DC: AACC Press, 2004, 192 pp., \$49.00 (\$39.00 AACC members), softcover. ISBN 1-59425-004-9.. Clinical Chemistry, 2005, 51, 1568-1568.	3.2	0
130	Comparison of the Associations of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis Study. Circulation, 2004, 110, 2687-2693.	1.6	135
131	Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. American Journal of Cardiology, 2004, 93, 159-164.	1.6	157
132	The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1355-63.	2.3	216
133	Insights from apoB: from better diagnosis & therapy to the Medusa Hypothesis. Atherosclerosis Supplements, 2004, 5, 19-24.	1.2	9
134	Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Current Opinion in Lipidology, 2004, 15, 433-438.	2.7	53
135	Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. American Journal of Cardiology, 2003, 91, 1173-1177.	1.6	196
136	Effects on apoB-100 secretion and bile acid synthesis by redirecting cholesterol efflux from HepG2 cells. Journal of Lipid Research, 2003, 44, 527-532.	4.2	14
137	Comparison of the Associations of Apolipoprotein B and Low-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 2003, 108, 2312-2316.	1.6	122
138	Can Measurement of Serum Apolipoprotein B Replace the Lipid Profile Monitoring of Patients with Lipoprotein Disorders?. Clinical Chemistry, 2002, 48, 484-488.	3.2	48
139	How, when, and why to use apolipoprotein B in clinical practice. American Journal of Cardiology, 2002, 90, 48-54.	1.6	51
140	Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2001, 135, 447.	3.9	273
141	Regulation by retinoic acid of acylation-stimulating protein and complement C3 in human adipocytes. Biochemical Journal, 2001, 356, 445-452.	3.7	40
142	High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol. American Journal of Cardiology, 2001, 87, 792-793.	1.6	25
143	Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm. Atherosclerosis, 2000, 148, 215-229.	0.8	38
144	Reduced Body Weight, Adipose Tissue, and Leptin Levels Despite Increased Energy Intake in Female Mice Lacking Acylation-Stimulating Protein. Endocrinology, 2000, 141, 1041-1049.	2.8	34

#	ARTICLE	IF	CITATIONS
145	Divergent responses of the liver to increased delivery of glucose or fatty acids: implications for the pathogenesis of type IV hyperlipoproteinemia. <i>Atherosclerosis</i> , 1998, 137, 291-301.	0.8	8
146	The acylation-stimulating protein pathway and regulation of postprandial metabolism. <i>Proceedings of the Nutrition Society</i> , 1997, 56, 703-712.	1.0	24
147	The Role of the Liver in the Pathogenesis of Hyperlipidemia in Patients with End-St Age Renal Disease Treated with Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 1996, 16, 207-211.	2.3	5
148	The Effect of Individual Amino Acids on ApoB100 and Lp(a) Secretion by HepG2 Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 29136-29145.	3.4	17
149	The Adipsin-ASP Pathway and Regulation of Adipocyte Function. <i>Annals of Medicine</i> , 1994, 26, 389-393.	3.8	41
150	Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. <i>Atherosclerosis</i> , 1991, 89, 109-116.	0.8	65
151	Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. <i>Lipids</i> , 1991, 26, 495-499.	1.7	132
152	Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. <i>Atherosclerosis</i> , 1987, 65, 257-264.	0.8	67
153	Association of Hyperapobetalipoproteinemia with Endogenous Hypertriglyceridemia and Atherosclerosis. <i>Annals of Internal Medicine</i> , 1982, 97, 833.	3.9	267
154	Differences between the effects of practolol and propranolol on the diastolic properties of the left ventricle. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 21, 267-271.	4.7	1
155	The significance of early changes of positive and negative dp/dt following contrast ventriculography. <i>Catheterization and Cardiovascular Diagnosis</i> , 1976, 2, 337-345.	0.3	3